176 related articles for article (PubMed ID: 2248164)
1. [Evaluation of experimental proliferative vitreoretinopathy in rabbits].
Kuriyama S; Ohuchi T; Okada M; Yamakawa R; Yoshimura N; Honda Y
Nippon Ganka Gakkai Zasshi; 1990 Sep; 94(9):792-8. PubMed ID: 2248164
[TBL] [Abstract][Full Text] [Related]
2. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R
Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits.
Yu HG; Chung H
Korean J Ophthalmol; 1997 Dec; 11(2):98-105. PubMed ID: 9510652
[TBL] [Abstract][Full Text] [Related]
4. Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye.
Hida T; Chandler DB; Sheta SM
Graefes Arch Clin Exp Ophthalmol; 1987; 225(4):303-7. PubMed ID: 3653728
[TBL] [Abstract][Full Text] [Related]
5. The role of breakdown of the blood-retinal barrier in cell-injection models of proliferative vitreoretinopathy.
Sen HA; Robertson TJ; Conway BP; Campochiaro PA
Arch Ophthalmol; 1988 Sep; 106(9):1291-4. PubMed ID: 3415556
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermia reduces the occurrence of proliferative vitreoretinopathy in a rabbit model.
Yoshimura N; Kuriyama S; Ohuchi T; Takemura M; Honda Y; Hiraoka M
Invest Ophthalmol Vis Sci; 1992 Feb; 33(2):404-9. PubMed ID: 1740372
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of growth stimulating activity of the vitreous during PVR.
Yang CM; Cousins SW
Invest Ophthalmol Vis Sci; 1992 Jul; 33(8):2436-42. PubMed ID: 1634341
[TBL] [Abstract][Full Text] [Related]
8. Proliferative vitreo-retinal disorders: experimental models in vivo and in vitro.
Martini B
Acta Ophthalmol Suppl (1985); 1992; (201):1-63. PubMed ID: 1322004
[TBL] [Abstract][Full Text] [Related]
9. Bovine RPE heterotransplants simulate proliferative vitreoretinopathy (PVR) in rabbits.
Weinsieder A; Radtke ND; Currier GJ; Caple S; Presley E; Weinsieder G
Metab Pediatr Syst Ophthalmol (1985); 1987; 10(1):2-8. PubMed ID: 3509276
[TBL] [Abstract][Full Text] [Related]
10. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
Mandava N; Blackburn P; Paul DB; Wilson MW; Read SB; Alspaugh E; Tritz R; Barber JR; Robbins JM; Kruse CA
Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843
[TBL] [Abstract][Full Text] [Related]
11. Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Proctor lecture.
Machemer R
Invest Ophthalmol Vis Sci; 1988 Dec; 29(12):1771-83. PubMed ID: 3056866
[No Abstract] [Full Text] [Related]
12. Preretinal membrane formation in rabbit eyes after intravitreal transplantation of cultured astrocytes.
Mishima N; Yamashita H; Ishii Y; Hori S
Jpn J Ophthalmol; 1989; 33(4):501-18. PubMed ID: 2696800
[TBL] [Abstract][Full Text] [Related]
13. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.
Khawly JA; Saloupis P; Hatchell DL; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1991; 229(5):464-7. PubMed ID: 1937080
[TBL] [Abstract][Full Text] [Related]
14. Induction of experimental proliferative vitreoretinopathy in the rabbit eye by intravitreal injections of fibroblast growth factor.
Baudouin C; Fredj-Reygrobellet D; Ettaiche M; Barritault D; Gastaud P; Lapalus P
Lens Eye Toxic Res; 1992; 9(3-4):505-11. PubMed ID: 1284520
[No Abstract] [Full Text] [Related]
15. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Kuo HK; Wu PC; Yang PM; Chen YH; Wu YC; Hu DN
J Ocul Pharmacol Ther; 2007 Feb; 23(1):14-20. PubMed ID: 17341145
[TBL] [Abstract][Full Text] [Related]
16. Irradiation pretreatment before fibroblast implantation in experimental PVR.
Velikay M; Stolba U; Wedrich A; Datlinger P; Binder S; Handl-Zeller L
Int Ophthalmol; 1993 Aug; 17(4):191-3. PubMed ID: 8112965
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages.
Kirchhof B; Sorgente N
Dev Ophthalmol; 1989; 16():1-53. PubMed ID: 2676632
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of drug treatments for proliferative vitreoretinopathy using vitreous microtensiometry.
Moorhead LC; Sepahban S; Armeniades CD
Ann Ophthalmol; 1991 Sep; 23(9):349-55. PubMed ID: 1741609
[TBL] [Abstract][Full Text] [Related]
19. N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina.
Steinhorst UH; Chen EP; Machemer R; Hatchell DL
Exp Eye Res; 1993 Apr; 56(4):489-95. PubMed ID: 8500561
[TBL] [Abstract][Full Text] [Related]
20. Panretinal photocoagulation aggravates experimental proliferative vitreoretinopathy.
Algvere PV; Hallnäs K; Dafgård E; Höög A
Graefes Arch Clin Exp Ophthalmol; 1990; 228(5):461-6. PubMed ID: 2227493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
